Kacip Fatimah for Menopausal Symptoms: What the Human Trials Actually Show

Of everything claimed for kacip fatimah, menopausal symptom relief is the one benefit with real human trial data behind it — a single, reasonably sized, sixteen-week randomised trial, plus a second trial of a combination product. That is a genuinely different evidentiary position from the pregnancy claim or the vaginal-tightening marketing, and this page treats it that way. It is also, on close reading, one small unreplicated trial with a result that does not entirely match its own proposed mechanism, and a combination trial that cannot tell you what kacip fatimah itself contributed. Both things are true at once.

Table of Contents

  1. What the Norhayati Trial Actually Found
  2. The Puzzle: Symptom Relief Without a Hormonal Signature
  3. The Combination-Product Trial
  4. The Placebo Problem in Hot-Flush Trials
  5. What Two Small Trials Cannot Tell You
  6. Bone Health Claims Riding on the Same Evidence
  7. Comparators That Have Actually Been Tested
  8. A Practical, Honest Way to Try It
  9. Key Research Papers
  10. Connections
  11. Featured Videos

What the Norhayati Trial Actually Found

The one substantial human trial behind kacip fatimah's menopause reputation was conducted in Kelantan, Malaysia, and published in the Journal of Medicinal Food in 2014. It was a randomised, double-blind, placebo-controlled, parallel-group study running sixteen weeks in healthy pre- and postmenopausal women aged 40–60. Subjects received either 400 mg per day of a proprietary Labisia pumila var. alata water extract or placebo. A total of 197 subjects completed analysis — 102 on the herb, 95 on placebo — which is a respectable size for a phytomedicine trial, larger than most botanical menopause studies that make it into print.

Outcomes were measured with the Women's Health Questionnaire, a validated nine-domain instrument covering mood, somatic symptoms, memory and concentration, vasomotor symptoms, sleep, menstrual symptoms, sexual behaviour, anxiety and attractiveness. Relative to placebo, the herbal group showed improvement in memory and concentration (8.3%), vasomotor symptoms (15.9%), menstrual symptoms (11.8%), and sleep problems (31.0%). The single largest effect reported was on the anxiety item "I get frightened or panic feelings for apparently no reason at all," which fell 53% compared with placebo. Cardiovascular markers also improved: total cholesterol and LDL cholesterol both fell in the treatment group. Reproductive hormones were also measured directly in the postmenopausal subgroup — luteinizing hormone, follicle-stimulating hormone, and 17β-estradiol — and none changed. The trial's own safety profile was reported as normal throughout.

Read plainly, that is a real signal in a real randomised trial: several self-reported quality-of-life domains improved more on the herb than on placebo, with no adverse hormonal or safety signal over sixteen weeks. It is also, by design, a single trial, from a single research group, never independently replicated in the decade since.

Back to Table of Contents

The Puzzle: Symptom Relief Without a Hormonal Signature

Here is the detail worth not smoothing over. The entire proposed mechanism for kacip fatimah easing menopausal symptoms is phytoestrogenic — weak plant-derived compounds occupying oestrogen receptors left under-stimulated once the ovaries stop producing oestradiol, damping the vasomotor and mood instability that follows. If that mechanism were operating as described, some downstream signature in the hypothalamic-pituitary-ovarian axis would be a reasonable thing to look for: LH and FSH rise sharply at menopause specifically because oestrogen's negative feedback on the pituitary is gone, so a treatment supplying oestrogen-like activity would be expected, at least in principle, to blunt that rise. The Norhayati trial measured exactly this, in the subgroup where it would show most clearly, and found no change in LH, FSH, or estradiol.

There are several honest candidate explanations, and the trial does not let you pick between them. Sixteen weeks may simply be too short a window to move gonadotropins measurably even if a real receptor-level effect exists. The Women's Health Questionnaire is a subjective, self-reported instrument, and hot flush frequency in particular is known to be highly placebo-responsive (see below) — so some or all of the reported benefit could be real symptom improvement occurring through a non-hormonal route: antioxidant, anti-inflammatory, or a central nervous system effect unrelated to the classic oestrogen-receptor story the marketing tells. Or the herb's action could be tissue-selective in a way that spares the hypothalamic-pituitary axis specifically while still affecting peripheral tissues — which would tie into the genuinely unresolved question of exactly what kacip fatimah's oestrogen-receptor activity even does, examined in full on this hub's oestrogen receptor page. What should not happen is treating "improved symptoms" and "phytoestrogenic mechanism" as the same finding twice confirmed by one trial. The trial confirms the first. It does not confirm the second, and on its own hormone panel, arguably undercuts it.

Back to Table of Contents

The Combination-Product Trial

The second human trial, published in Food & Nutrition Research in 2020, was a randomised, placebo-controlled study of standardised Labisia pumila and Eurycoma longifolia (tongkat ali) extracts taken together, in peri- and postmenopausal women, measuring hot flushes, quality of life, hormone levels and lipid profile. This design reflects the real Malaysian market accurately — combination women's-health tonics pairing the two herbs are common retail products — but it carries the limitation every combination trial carries: whatever the result, positive or negative, it cannot be attributed to either herb individually. Tongkat ali has its own pharmacology, including effects on testosterone and cortisol that are unrelated to any oestrogen-receptor mechanism, so a positive finding in this trial tells you the combination did something. It does not tell you kacip fatimah did.

Taken together, the human evidence base for menopausal symptom relief is one real trial of the single herb, unreplicated, with a puzzle in its own hormone data, plus one trial of a two-herb combination that cannot isolate either ingredient's contribution. That is a genuinely different, and better, evidentiary position than kacip fatimah's other claimed benefits. It is not, on its own, enough to call the herb an established treatment.

Back to Table of Contents

The Placebo Problem in Hot-Flush Trials

Hot flushes carry one of the highest placebo response rates in clinical medicine, commonly 30% or more reduction in frequency on inert treatment alone, which is precisely why an uncontrolled or open-label report of "it helped my hot flushes" is close to worthless as evidence and why a properly blinded placebo arm matters more here than in almost any other symptom category. The scale of the problem is visible in how much data it has taken to get even a provisional answer for a much more intensively studied class of phytoestrogens. A 2013 Cochrane systematic review of phytoestrogens for menopausal vasomotor symptoms, and later meta-analyses specifically of red clover (Trifolium pratense) isoflavone extracts, drew on dozens of randomised trials and thousands of participants and still reached a measured, hedged conclusion rather than a clean "yes, it works" — effects were inconsistent across trials, often small, and sensitive to formulation and dose. If that much data leaves the phytoestrogen-for-hot-flushes question only partially resolved, two trials of kacip fatimah cannot resolve it for this herb specifically. It can be encouraging. It cannot be conclusive.

Back to Table of Contents

What Two Small Trials Cannot Tell You

Beyond the placebo issue, there are questions neither trial was designed or powered to answer. Neither measured symptoms beyond sixteen weeks, so nothing is known about whether benefit persists, plateaus, or fades with continued use over the years menopausal symptoms typically last. Neither trial has been replicated by a research group independent of the original Malaysian teams, which matters because independent replication is one of the more reliable filters against a single group's analytic choices or an unlucky (or lucky) randomisation producing a result that does not generalise. And neither trial recruited specifically for severe, treatment-refractory vasomotor symptoms, so it is not known whether kacip fatimah offers anything to women whose flushes are bad enough that they have already tried and failed other options. None of this means the existing trials are wrong. It means they answer a narrower question — "does a proprietary 400 mg extract outperform placebo over sixteen weeks in a general perimenopausal population on a subjective questionnaire" — than "does kacip fatimah treat menopause," and the second, broader claim is what gets sold.

Back to Table of Contents

Bone Health Claims Riding on the Same Evidence

Bone protection is frequently bundled into kacip fatimah's menopause marketing, and it deserves to be separated out explicitly because the evidence behind it is a different body of work entirely — and it is exclusively animal work. The ovariectomised rat, which reproduces the sharp oestrogen fall of menopause surgically, is the standard model, and a specific cluster of Malaysian research groups has used it repeatedly: bone markers and bone calcium; bone-related gene expression; bone strength across dose and duration, with a companion micro-CT study of microarchitecture; and a further 2012 study reporting that the extract reduced bone loss and preserved bone strength in the same model. A 2018 systematic review that screened 399 candidate studies down to 21 methodologically acceptable ones on Malaysian traditional herbs and osteoporotic rat models found that nine of those 21 were on Labisia pumila specifically — more than on Piper sarmentosum or Eurycoma longifolia, the other two herbs reviewed — and concluded that kacip fatimah recorded better anti-osteoporotic effects than tongkat ali, most of whose studies failed to preserve bone strength in the same model.

That is a reasonably consistent animal literature, and it is the strongest mechanistic case kacip fatimah has for anything. It is still exclusively a rat literature. No human trial of kacip fatimah has measured bone mineral density by DEXA scan over any meaningful period, and none has measured fractures — the outcome that actually matters, since bone density is a surrogate marker and a hip fracture, not a T-score, is what changes a life. The two human trials above measured symptoms and blood chemistry over sixteen weeks, not skeletal outcomes over years. If you are managing osteopenia or osteoporosis, the interventions with actual fracture-reduction evidence in humans — adequate vitamin D and calcium, resistance and impact-loading exercise, fall-prevention balance work, and where indicated prescription therapy — remain the ones to build a plan on. A herb with encouraging rat data belongs alongside those measures at most, not in place of them.

Back to Table of Contents

Comparators That Have Actually Been Tested

The most useful context for two small kacip fatimah trials is what a genuinely mature evidence base for a menopause remedy looks like. Black cohosh has multiple randomised trials and several meta-analyses behind it and is still the subject of legitimate, ongoing disagreement among reviewers about whether it clearly beats placebo. Soy and red clover isoflavones have been tested in dozens of randomised trials pooled into Cochrane and independent meta-analyses, with effects that are real in aggregate but modest and inconsistent trial-to-trial. A separate systematic review specifically of phytoestrogens and sexual function in menopausal women — the closest published comparator to the sexual-wellness claims examined on this hub's sexual wellness page — exists for that class of compounds generally. No such review or replication programme exists yet for kacip fatimah specifically, on any endpoint. That is not a criticism of the herb; it is simply a much earlier stage of the evidence lifecycle than any of these comparators, and it is worth calibrating expectations against that stage rather than against the confident tone of retail marketing copy.

Back to Table of Contents

A Practical, Honest Way to Try It

If you decide to try kacip fatimah for menopausal symptoms despite the limits above, the trial itself suggests a reasonable, low-cost way to find out whether it is doing anything for you personally. Use a dose in the range the Norhayati trial tested — check the product label for a standardised var. alata water extract rather than an unspecified powder, since that is the material actually studied — for a defined period of eight to twelve weeks, and keep a simple written log of hot flush frequency and severity before you start and at the end. Given how large the placebo response is for this symptom class, a vague retrospective impression of "I think it's better" is not trustworthy evidence even about your own response; a dated log is. If nothing measurable has changed after a defined trial period, stop. If you are on tamoxifen, an aromatase inhibitor, hormone replacement therapy, or have a personal history of an oestrogen-sensitive condition, read the oestrogen receptor page on this hub before starting, since that is where the relevant caution is explained in full rather than repeated here.

Back to Table of Contents

Key Research Papers

  1. Norhayati MN, George A, Hazlina NH, et al. (2014). Efficacy and safety of Labisia pumila var alata water extract among pre- and postmenopausal women. Journal of Medicinal Food. — PubMed
  2. Chinnappan SM, George A, Evans M, Anthony J (2020). Efficacy of Labisia pumila and Eurycoma longifolia standardised extracts on hot flushes, quality of life, hormone and lipid profile of peri-menopausal and menopausal women: a randomised, placebo-controlled study. Food & Nutrition Research. — PubMed
  3. Shuid AN, Ping LL, Muhammad N, Mohamed N, Soelaiman IN (2011). The effects of Labisia pumila var. alata on bone markers and bone calcium in a rat model of post-menopausal osteoporosis. Journal of Ethnopharmacology. — PubMed
  4. Mohd Effendy N, Abdullah S, Yunoh MF, Shuid AN (2015). Time and dose-dependent effects of Labisia pumila on the bone strength of postmenopausal osteoporosis rat model. BMC Complementary and Alternative Medicine. — PubMed
  5. Fathilah SN, Mohamed N, Muhammad N, Mohamed IN, Soelaiman IN, Shuid AN (2013). Labisia pumila regulates bone-related genes expressions in postmenopausal osteoporosis model. BMC Complementary and Alternative Medicine. — PubMed
  6. Labisia pumila prevents complications of osteoporosis by increasing bone strength in a rat model of postmenopausal osteoporosis (2012). Evidence-Based Complementary and Alternative Medicine. — PubMed
  7. Nadia ME, Nazrun AS, Norazlina M, et al. (2012). The anti-inflammatory, phytoestrogenic, and antioxidative role of Labisia pumila in prevention of postmenopausal osteoporosis. Advances in Pharmacological Sciences. — PubMed
  8. Mohammad NA, Razaly NI, Rani MDM, Aris MSM, Effendy NM (2018). An evidence-based review: the effects of Malaysian traditional herbs on osteoporotic rat models. Malaysian Journal of Medical Sciences. — PubMed
  9. Phytoestrogens for menopausal vasomotor symptoms (2013). Cochrane Database of Systematic Reviews. — PubMed
  10. Evaluation of clinical meaningfulness of red clover (Trifolium pratense) extract to relieve hot flushes and menopausal symptoms: a systematic review and meta-analysis of randomised controlled trials (2021). Nutrients. — PubMed
  11. Wang Y, Yan F, Xu DQ, et al. (2025). Traditional uses, botany, phytochemistry, pharmacology and applications of Labisia pumila: a comprehensive review. Journal of Ethnopharmacology. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents